Alaunos’ runway ends before New Year's, as TCR biotech shrinks staff, seeks sale
Alaunos Therapeutics, a TCR-T biotech formerly known as Ziopharm Oncology, will shutter its lead program, lay off 60% of staff and seek a sale or …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
